Corporate News Report
The Norwegian pharmaceutical firm Vistin Pharma ASA (ticker VISTN.OL) experienced a modest decline in its share price during the 24‑hour window concluding at 03:49 AM Central Europe on Friday, 23 October 2026. The stock fell 1.36 %, trading at approximately NOK 18.10 on the Oslo Børs.
Market Snapshot
- Shares outstanding: 44.3 million
- Market capitalisation: NOK 802.6 million
- 24‑hour trading volume: NOK 82,200
- Average price over last 200 days: NOK 20.58
- 52‑week high: NOK 23.50 (25 February 2026)
- 52‑week low: NOK 17.70 (20 August 2026)
The company’s shares have shown a flat trend since the previous month‑end, reflecting a period of consolidation for investors.
Comparative Performance of Peer Stocks
| Stock | Ticker | 24‑hour change | Current price | Market cap |
|---|---|---|---|---|
| Omda | OMDA.OL | –1.67 % | NOK 45.50 | NOK 1.1 bn |
| Huddly | 14B0.F | +9.22 % | EUR 2.12 | EUR 79.6 mn |
| Haugesund Sparebank | Y7I.F | 0 % | EUR 15.00 | EUR 73.9 mn |
| Norse Atlantic ASA | NORSE.OL | +3.70 % | NOK 0.27 | NOK 798.7 mn |
| Aker Biomarine ASA | NO0010886625.SG | +6.64 % | NOK 122.00 | NOK 932.3 mn |
While Vistin Pharma’s shares slipped modestly, Huddly and Aker Biomarine posted notable gains, signalling differential investor sentiment across the sector.
Company Profile
Vistin Pharma ASA, headquartered in Oslo, Norway, operates through its subsidiary Vistin Pharma AS. The company specialises in the manufacture of active pharmaceutical ingredients (APIs), specifically metformin hydrochloride, as well as direct‑compressible granulates, tablets, and finished‑dose formulations for global pharmaceutical partners. Established in 2015, Vistin Pharma maintains a robust production capability that supports the worldwide demand for metformin, a cornerstone therapy for type 2 diabetes. The firm’s website, www.vistin.com , provides further insight into its product portfolio and corporate initiatives.
Outlook
With a stable market capitalisation and a broad pipeline of API products, Vistin Pharma remains positioned to benefit from the ongoing growth in the diabetes treatment market. However, short‑term volatility—illustrated by the recent 1.36 % decline—may continue to reflect broader market dynamics and sector‑specific supply chain considerations. Investors should monitor the company’s quarterly earnings and any strategic announcements that could influence its share performance in the coming months.